Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive...
SHA: 600267
Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors
China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...
Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic...
Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...